Intra-Cellular Therapies Inc (NASDAQ: ITCI) started the day on Wednesday, with a price decrease of -0.09% at $128.46, before settling in for the price of $128.58 at the close. Taking a more long-term approach, ITCI posted a 52-week range of $63.30-$128.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 7627.06% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 23.01%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 183.15%. This publicly-traded company’s shares outstanding now amounts to $106.24 million, simultaneously with a float of $98.98 million. The organization now has a market capitalization sitting at $13.66 billion. At the time of writing, stock’s 50-day Moving Average stood at $111.20, while the 200-day Moving Average is $84.63.
Intra-Cellular Therapies Inc (ITCI) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Intra-Cellular Therapies Inc’s current insider ownership accounts for 6.91%, in contrast to 82.81% institutional ownership. According to the most recent insider trade that took place on Dec 04 ’24, this organization’s Chairman and CEO sold 51,000 shares at the rate of 85.80, making the entire transaction reach 4,375,659 in total value, affecting insider ownership by 1,070,329. Preceding that transaction, on Dec 05 ’24, Company’s Chairman and CEO sold 51,697 for 84.08, making the whole transaction’s value amount to 4,346,842. This particular insider is now the holder of 1,070,329 in total.
Intra-Cellular Therapies Inc (ITCI) Earnings and Revenue Records
Intra-Cellular Therapies Inc’s EPS increase for this current 12-month fiscal period is 183.15% and is forecasted to reach 4.02 in the upcoming year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
Let’s observe the current performance indicators for Intra-Cellular Therapies Inc (ITCI). It’s Quick Ratio in the last reported quarter now stands at 6.23. The Stock has managed to achieve an average true range (ATR) of 1.00. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 20.06.
In the same vein, ITCI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.72, a figure that is expected to reach -0.11 in the next quarter, and analysts are predicting that it will be 4.02 at the market close of one year from today.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
If we take a close look at the recent performances of Intra-Cellular Therapies Inc (NASDAQ: ITCI), its last 5-days Average volume was 1.5 million that shows plunge from its year to date volume of 3.98 million. During the previous 9 days, stock’s Stochastic %D was recorded 77.25% While, its Average True Range was 0.66.
Raw Stochastic average of Intra-Cellular Therapies Inc (ITCI) in the period of the previous 100 days is set at 99.07%, which indicates a major rise in contrast to 72.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.86% that was lower than 57.56% volatility it exhibited in the past 100-days period.
